The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000808347
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
3/06/2026
Date registered
Help: Date registered
6/07/2026
Date last updated
Help: Date last updated
6/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
6/07/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
A Prospective Cohort Study of Percutaneous Needle Biopsy, Morphologic and Molecular Evaluation of Uterine Tumours with Imaging Features of Concern for Sarcoma
Scientific title
A Prospective Cohort Study of Percutaneous Needle Biopsy, Morphologic and Molecular Evaluation of Uterine Tumours with Imaging Features of Concern for Sarcoma
Additional trial identifiers [1] 317453 0
ASSG98
Universal Trial Number (UTN)
Trial acronym
GYNSarc
Related trial records

Health condition
Health condition(s) studied:
Uterine sarcoma 342150 0
Condition category
Condition code
Cancer 338266 338266 0 0
Sarcoma (also see 'Bone') - soft tissue

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
A one-off percutaneous uterine needle biopsy (PUB) will be performed on the participant by a gynecology oncologist at the hospital site where the patient is being treated. The PUB procedure will be carried out in line with usual practice for core biopsies of pelvic, retroperitoneal and intra-abdominal sarcomas. PUB is a day procedure typically taking 10 to 15 minutes to complete and involves sophisticated imaging techniques (eg ultrasound, CT or MRI) to localise the area of the tumour. Then, under local anaesthesia, a small cylinder with a cutting chamber is inserted into the mass to remove multiple small cores of that tissue for pathologists to examine. For this study, PUBs will be performed with the coaxial technique using 14 or 16-gauge semiautomatic cutting needles (Bard ‘‘Mission’’ disposable core biopsy instrument). The needles utilised will be 10 to 15-cm long with 20 mm penetration depth. A minimum 4 but preferably 6 samples will be obtained from each mass in all patients. Adherence to the intervention will be confirmed via review of medical records. The timing of the procedure will occur according to specialist recommendation and will not delay the scheduling of any recommended surgery. The biopsy results will be discussed at the GYN Oncology MDT in order to determine the next step in the patient’s management which may or may not include surgery. The MDT’s recommendations will be discussed with the patient at her scheduled post procedure clinic visit. Results and the decisions made will be reviewed from the medical records and recorded in the study database.
Intervention code [1] 334245 0
Diagnosis / Prognosis
Intervention code [2] 334246 0
Early detection / Screening
Description of the comparator or control
All participants will act as their own control group. The rate of concordance between their biopsy results and the findings on evaluation of their resected specimen will be measured by a qualified reference study pathologist. If surgery is not performed then the comparator will be the clinical course of the uterine mass at 6 and 12 month follow ups.
Control group
Active

Outcomes
Primary outcome [1] 345619 0
The rate of concordance between the biopsy results and the findings on evaluation of any resected specimens or the clinical course of uterine mass at 6 and 12 months of clinic follow up if surgery is not performed.
Timepoint [1] 345619 0
After surgical removal of uterine mass or at 6 and 12 month clinic follow up visits.
Primary outcome [2] 346050 0
Tumour diagnosis
Timepoint [2] 346050 0
After consent and before any planned surgery.
Secondary outcome [1] 462444 0
Feasibility of implementing the PUB procedure for this patient group.
Timepoint [1] 462444 0
At the end of recruitment.
Secondary outcome [2] 464439 0
Safety of PUB procedure for this patient group.
Timepoint [2] 464439 0
Monthly, at trial management meetings.

Eligibility
Key inclusion criteria
1. Not pregnant
2. Age greater than or equal to 18 years
3. Women with known or suspected cancer predisposition syndromes including pathogenic mutations in BRCA1 or BRCA2 and mismatch repair genes (Lynch syndrome) are eligible
4. Uterine mass greater than or equal to 5cm at baseline with rapid growth on sequential assessment, or suspicious features on MRI
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Healthy volunteers
No
Key exclusion criteria
1. Inability to give informed consent.
2. The radiologists’ expert opinion is that the particular lesion is technically unsuitable for PUB
3. Bleeding tendency.
4. Serious concurrent comorbidities that in the surgeon’s or radiologist’s opinion would pose a contraindication to PUB.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA

Funding & Sponsors
Funding source category [1] 322024 0
Other Collaborative groups
Name [1] 322024 0
Australia and New Zealand Sarcoma Association
Country [1] 322024 0
Australia
Primary sponsor type
Other Collaborative groups
Name
Australia and New Zealand Sarcoma Association
Address
Country
Australia
Secondary sponsor category [1] 324902 0
None
Name [1] 324902 0
Address [1] 324902 0
Country [1] 324902 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320557 0
Central Adelaide Local Health Network HREC
Ethics committee address [1] 320557 0
Ethics committee country [1] 320557 0
Australia
Date submitted for ethics approval [1] 320557 0
Approval date [1] 320557 0
30/04/2025
Ethics approval number [1] 320557 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150866 0
Prof Gelareh Farshid
Address 150866 0
SA Pathology, Frome Road, Adelaide SA 5000
Country 150866 0
Australia
Phone 150866 0
+61 0431522196
Fax 150866 0
Email 150866 0
Contact person for public queries
Name 150867 0
Janina Chapman
Address 150867 0
Australia and New Zealand Sarcoma Association, 305 Grattan Street, Melbourne VIC 3000
Country 150867 0
Australia
Phone 150867 0
+61 0414316490
Fax 150867 0
Email 150867 0
Contact person for scientific queries
Name 150868 0
Gelareh Farshid
Address 150868 0
SA Pathology, Frome Road, Adelaide SA 5000
Country 150868 0
Australia
Phone 150868 0
+61 0431522196
Fax 150868 0
Email 150868 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.